TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24666170
Drug: Plasma treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma treatment (PlasmaDerm® VU‐2010)
Study: 24273973
Drug: IV group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV group (intravenous injection of 2.5 mg droperidol)
Study: 24273973
Drug: P6 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: P6 group (Neiguan point injection of droperidol)
Study: 24273973
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 mL 0.9% normal saline injection)
Study: 21733304
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Ca plus 2 mg Cu and 12 mg Zn
Study: 21733304
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Ca plus maize starch placebo
Study: 21733304
Drug: Zn supplementation
Normalized name: zinc bandage with supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn supplementation with intakes < 8.0 mg/d
Study: 21733304
Drug: Zn intakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn intakes ≥ 8.0 mg/d
Study: 21733304
Drug: Mg intakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg intakes < 237 mg/d, Cu intakes < 0.9 mg/d, Zn intakes < 8.0 mg/d
Study: 17343005
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or Paroxetine (Western medicinal treatment)
Study: 9478327
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (50 mg/day, Prontogest, AMSA, Italy)
Study: 9478327
Drug: Micronized vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized vaginal progesterone (200 mg/day Esolut, Angelini, Italy)
Study: 8179132
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation with propofol (bolus dose 18 mg over 5.4 s; lockout period 1 min)
Study: 8179132
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol infusion (3.6 mg.kg‐1.h‐1)
Study: 2966600
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 0.125% bupivacaine and sufentanil 2 micrograms/ml
Study: 2966600
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 0.25% bupivacaine and 0.125% bupivacaine infusion
Study: 30887868
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg pine bark extract
Study: 30633368
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg, twice daily for 7 days)
Study: 26274827
Drug: Combined nutraceutical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nutraceutical containing red yeast rice (Dif1Stat(®), including 5 mg monacolin K) and 610 mg PUFAs
Study: 26274827
Drug: Phytosterols 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols 1600 mg/die
Study: 23253886
Drug: Glutamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.4 g/kg/day of 20% solution of N(2)-L-alanyl-L-glutamine)
Study: 19786383
Drug: MLCT oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLCT oil (25-30 g daily for 8 weeks)
Study: 19786383
Drug: LCT oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT oil (25-30 g daily for 8 weeks)
Study: 15046230
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) for localized carcinoma of the prostate
Study: 9551777
Drug: Hydrocortisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (20 mg orally, twice daily for 10 days)
Study: 29658070
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) with low-level laser irradiation (LLLI)
Study: 29658070
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment without PBM (Control group)
Study: 26354678
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of zidovudine (400 mg)
Study: 26354678
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of zidovudine (600 mg)
Study: 26354678
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of zidovudine
Study: 22619027
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG (200 IU per day) in late follicular phase
Study: 22619027
Drug: Standard long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard long protocol with gonadotropin administration (10,000 IU hCG for final maturation)
Study: 22619027
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (low-dose hCG)
Study: 18186581
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment on Zhong‐Ji (CV‐3), Guan‐Yuan (CV‐4) and Qi‐Hai (CV‐6) for 10 days
Study: 18186581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no moxibustion treatment)
Study: 10340104
Drug: Androgen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen therapy for pubertal delay
Study: 10340104
Drug: Long-term treatments
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatments to alter final adult height
Study: 7603216
Drug: Enriched wafer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched wafer (3.5 mg beta-carotene, 5.2 mg iron, 7.8 g fat)
Study: 7603216
Drug: Vegetable group
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable group (3.5 mg beta-carotene, 4.8 mg iron, 4.4 g fat)
Study: 2196208
Drug: Sucralfate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (4 g per day)
Study: 2196208
Drug: Sucralfate tablets
Normalized name: Sucralfate Tablets
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate tablets (2 g per day)
Study: 31764511
Drug: Oral 3000
Normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 3000 IU/d retinol for 8 weeks
Study: 31764511
Drug: Oral 6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 6000 IU/d retinol for 8 weeks
Study: 28320537
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen acid (Advil)
Study: 28320537
Drug: 512 mg
Normalized name: chromic chloride 0.00512 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 512 mg ibuprofen sodium dihydrate (Advil Sodium)
Study: 23194830
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (rTMS applied to the DLPFC; 10 sessions; 1 session a day; frequency = 10 Hz; intensity = 110% of motor threshold)
Study: 23194830
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham coil)
Study: 19246724
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg oral dose
Study: 11701404
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% azelaic acid cream plus oral minocycline
Study: 11701404
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% azelaic acid cream (maintenance therapy)
Study: 11701404
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (control during maintenance phase)
Study: 9331000
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (2-16 mg, single and repeated once-daily doses)
Study: 29705177
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (n=45): Three daily sets of single-leg standing (1 min/leg/set) and squatting (5-6 repetitions/set).
Study: 29705177
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and vitamin D group (n=43): Combination of exercise and vitamin D supplementation.
Study: 7503183
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined replacement therapy (group B): 2 mg of estradiol, 1 mg of estriol, and 1 mg of norethisterone acetate daily for 12 days per month.
Study: 7503183
Drug: Sequential estrogen-progestogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential estrogen-progestogen replacement therapy (group A): 2 mg of estradiol valerate daily and 5 mg of medroxyprogesterone acetate daily for 12 days per month.
Study: 2196946
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (trained for 8 weeks, one hour a week, continued exercising twice daily for one year)
Study: 2196946
Drug: Non-specific counselling
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific counselling (same attendance schedule, no training, just sit and relax twice a day)
Study: 7381637
Drug: Phenobarbital 5
Normalized name: phenobarbital 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 5 mg/kg in a single daily dose
Study: 30477009
Drug: Triplet-based induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet-based induction therapy with Carfilzomib, Lenalidomide, and Dexamethasone followed by Lenalidomide maintenance therapy
Study: 23295472
Drug: Low-frequency transcutaneous
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency transcutaneous electrical nerve stimulation (LF-TENS) for 30 minutes daily for 10 days
Study: 23295472
Drug: Sham TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TENS for 30 minutes daily for 10 days
Study: 12926339
Drug: Systemic hemostatic
Normalized name: Other systemic hemostatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic hemostatic therapy, antisecretory drugs, methods of endoscopic hemostasis
Study: 9378690
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75-225 mg) once daily
Study: 29949328
Drug: Tongkuaixiao ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongkuaixiao ointment (TKXO)
Study: 21992858
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D (1000 IU for <1 year and 2000 IU for >1 year) once a day for 5 days
Study: 21992858
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D (1000-2000 IU per day for 5 days)
Study: 15811151
Drug: Complete sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete sequential video
Study: 12723743
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine (10, 5, and 5 mg/kg) at 24-hour intervals
Study: 12723743
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg at 12-hour intervals)
Study: 12723743
Drug: Ibuprofen (prophylaxis)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (prophylaxis)
Study: 10229431
Drug: Active nonsteroidal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nonsteroidal antiinflammatory drugs (n=352)
Study: 8522712
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (525 mg/24 h)
Study: 8522712
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (1,050 mg/24 h)
Study: 8522712
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (2,100 mg/24 h)
Study: 27828927
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg ketamine administered intravenously during ECT under propofol anesthesia
Study: 27828927
Drug: Isovolumetric placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolumetric placebo (normal saline) administered during ECT under propofol anesthesia
Study: 9728672
Drug: SSRIs (fluvoxamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (fluvoxamine, fluoxetine, paroxetine, sertraline) at recommended daily dosages for 6 weeks
Study: 7645712
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy by facemask
Study: 2520418
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (5 mg/kg body weight)
Study: 2520418
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine and placebo
Study: 1092276
Drug: Monthly sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulphadoxine-pyrimethamine
Study: 30120600
Drug: Sumatriptan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (2 x 50 mg)
Study: 24578607
Drug: Cervical interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL or 6 mg of nonparticulate betamethasone
Study: 20660280
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A (HD-VA) supplement (209.8 micromol; 60 mg)
Study: 20660280
Drug: Stable isotope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable isotope (SI)-labeled vitamin A (17.5 micromol; 5 mg)
Study: 18355327
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus 1 OAD
Study: 18355327
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus >1 OAD
Study: 18355327
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (both groups)
Study: 9438978
Drug: 3 capsules
Normalized name: Xymogen Medcaps T3 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules of green tea extract (225 mg EGCg, 7.5 mg EGC)
Study: 9438978
Drug: 5 capsules
Normalized name: Xymogen Optimag 125 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules of green tea extract (375 mg EGCg, 12.5 mg EGC)
Study: 9438978
Drug: 7 capsules
Normalized name: Menaquinone-7 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 capsules of green tea extract (525 mg EGCg, 17.5 mg EGC)
Study: 2773967
Drug: Orgotein (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein (8 mg to 32 mg) administered as an intra-articular injection once a week for three weeks
Study: 2773967
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as an intra-articular injection once a week for three weeks
Study: 31408137
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP goal < 120 mm Hg, n=355)
Study: 31408137
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP goal < 140 mm Hg, n=315)
Study: 31408137
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP goal < 120 mm Hg)
Study: 31408137
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP goal < 140 mm Hg)
Study: 24367678
Drug: Nevirapine-based antiretroviral
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine-based antiretroviral therapy
Study: 21310350
Drug: Apical resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical resection at 90° angle with ultrasonic preparation and MTA obturation (Group 2)
Study: 21310350
Drug: Apical resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical resection at ∼45° angle with ultrasonic preparation and MTA obturation (Group 4)
Study: 15163773
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level 0.5 ng/mL or less
Study: 15163773
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level 0.6 to 1.0 ng/mL
Study: 15163773
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level 1.1 to 2.0 ng/mL
Study: 15163773
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level 2.1 to 3.0 ng/mL
Study: 15163773
Drug: PSA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA level 3.1 to 4.0 ng/mL
Study: 11210401
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (2.4 g doses)
Study: 9596048
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (n = 27)
Study: 3135734
Drug: Intravenous nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroprusside (NTP)
Study: 29308591
Drug: Intranasal ELI‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ELI‐200 (30‐mg oxycodone hydrochloride/3‐mg naltrexone HCl)
Study: 29308591
Drug: Intranasal oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxycodone immediate release (30‐mg oxycodone HCl)
Study: 29308591
Drug: Oral ELI‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ELI‐200 (30mg/3mg)
Study: 19198708
Drug: Oral dextromethorphan
Normalized name: dextromethorphan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextromethorphan (45 mg)
Study: 11372025
Drug: Baseline drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline drug resistance mutations
Study: 9656393
Drug: Artemether (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (150 and 100 mg) with mefloquine (750 and 500 mg)
Study: 9656393
Drug: Artesunate (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (150 and 100 mg) with mefloquine (750 and 500 mg)
Study: 3112428
Drug: 91-cm 3.0-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 91-cm 3.0-g weighted tube (Entriflex, Biosearch, Raritan, NJ)
Study: 27687347
Drug: Neostigmine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.05 mg/kg) and Atropine (0.01 mg/kg)
Study: 24742955
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dietary‐induced weight loss and exercise (D + E; n = 101)
Study: 22520138
Drug: PRV (pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRV (pentavalent rotavirus vaccine)
Study: 20019677
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (<30 g/day)
Study: 15810646
Drug: Rifaximin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin, 200 mg bid (Group R1: 39 pts)
Study: 15810646
Drug: Rifaximin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin, 400 mg bid (Group R2: 43 pts)
Study: 15810646
Drug: Mesalazine, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine, 400 mg bid (Group M1: 40 pts)
Study: 15810646
Drug: Mesalazine, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine, 800 mg bid (Group M2: 48 pts)
Study: 12375668
Drug: Prophylactic calcium
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic calcium (Ca) chloride or Ca gluconate at a dose linked to citrate infusion rate (1.0‐2.2 mg/kg/min)
Study: 12375668
Drug: Citrate administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate administration
Study: 7842770
Drug: Furosemide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (10 mg/m2 of body)
Study: 7842770
Drug: Amiloride (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (0.3 mg/m2 of body)
Study: 651283
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lanatosid C in saline
Study: 31923712
Drug: Whole Pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Pelvic Radiation Therapy (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis)
Study: 31923712
Drug: Prostate Only
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate Only Radiation Therapy (PORT, 68 Gy/25# to prostate)
Study: 31923712
Drug: Prostate Only
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate Only Radiation Therapy (PORT)
Study: 31923712
Drug: Whole Pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Pelvic Radiation Therapy (WPRT) and Prostate Only Radiation Therapy (PORT)
Study: 23235363
Drug: telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80 mg and aliskiren 300 mg
Study: 23235363
Drug: telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80 mg and eplerenone 50 mg